A Phase 2, Open Label, Single Arm Trial of TPI 287 in Patients With Advanced, Unresectable Pancreatic Cancer After Prior Treatment With a Gemcitabine-Based Therapy.

Trial Profile

A Phase 2, Open Label, Single Arm Trial of TPI 287 in Patients With Advanced, Unresectable Pancreatic Cancer After Prior Treatment With a Gemcitabine-Based Therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2014

At a glance

  • Drugs TPI 287 (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Cortice Biosciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Jun 2009 Planned end date changed from 1 Oct 2009 to 1 Apr 2010 as reported by ClinicalTrials.gov.
    • 05 Jun 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top